Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Retained Earnings (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Retained Earnings for 11 consecutive years, with -$171.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings changed N/A to -$171.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$171.8 million, a N/A change, with the full-year FY2025 number at -$171.8 million, changed N/A from a year prior.
  • Retained Earnings was -$171.8 million for Q4 2025 at Crescent Biopharma, down from -$79.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$54.8 million in Q2 2025 to a low of -$496.7 million in Q1 2025.
  • A 5-year average of -$369.2 million and a median of -$409.3 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: fell 21.66% in 2021, then surged 88.52% in 2025.
  • Crescent Biopharma's Retained Earnings stood at -$372.9 million in 2021, then dropped by 12.52% to -$419.6 million in 2022, then dropped by 8.79% to -$456.5 million in 2023, then dropped by 6.72% to -$487.1 million in 2024, then soared by 64.73% to -$171.8 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Retained Earnings are -$171.8 million (Q4 2025), -$79.4 million (Q3 2025), and -$54.8 million (Q2 2025).